Velleca Mark A. 4
4 · Black Diamond Therapeutics, Inc. · Filed Feb 15, 2024
Insider Transaction Report
Form 4
Velleca Mark A.
DirectorPRESIDENT & CEO
Transactions
- Award
Stock Option (Right to Buy)
2024-02-14+537,000→ 537,000 totalExercise: $4.86Exp: 2034-02-13→ Common Stock (537,000 underlying)
Footnotes (1)
- [F1]25% of the shares subject to this option shall vest and become exercisable on February 14, 2025, with the remainder vesting in 36 equal monthly installments thereafter.